"","AA_POS","MUTATION","GENE_ID","ALLELE.COUNT","Pathogenic","Genomic_location","ProteinID","MUTPRED.Score","Hypothesis","ALLELE.COUNT.log","AA","a4v","HSA","NHSA","a4vAHS","ConSurf_index"
"1",5,"R5C","MAPT",2,"","17:44039716:C:T","P10636",166.646341463415,"Gain of catalytic residue at E7 (P = 0.0864); Loss of disorder (P = 0.1946); Loss of glycosylation at P4 (P = 0.2166); Loss of solvent accessibility (P = 0.3854); Gain of sheet (P = 0.6509)",0.693147180559945,"R",-0.404,0,0,0,-1.053
"2",5,"R5L","MAPT",0.1,"P","17:44039717:G:T","P10636",215.365853658537,"Gain of stability (P = 0.0485); Loss of disorder (P = 0.1465); Loss of solvent accessibility (P = 0.1922); Loss of glycosylation at P4 (P = 0.2241); Gain of catalytic residue at E9 (P = 0.2984)",-2.30258509299405,"R",-0.404,0,0,0,-1.053
"3",13,"D13N","MAPT",1,"","17:44039740:G:A","P10636",147.158536585366,"Loss of phosphorylation at T17 (P = 0.1333); Loss of stability (P = 0.2348); Gain of relative solvent accessibility (P = 0.2363); Loss of disorder (P = 0.2447); Gain of glycosylation at T17 (P = 0.3274)",0,"D",-0.091,0,0,0,-1.055
"4",16,"G16V","MAPT",1,"","17:44039750:G:T","P10636",166.646341463415,"Loss of catalytic residue at A15 (P = 0.0601); Loss of disorder (P = 0.0672); Loss of phosphorylation at T17 (P = 0.2248); Loss of glycosylation at T17 (P = 0.3836); Loss of relative solvent accessibility (P = 0.5582)",0,"G",-0.239,0,0,0,-0.035
"5",17,"T17S","MAPT",1,"","17:44039752:A:T","P10636",30.2317073170732,"Loss of glycosylation at T17 (P = 0.1704); Loss of phosphorylation at T17 (P = 0.1742); Gain of disorder (P = 0.529); Gain of MoRF binding (P = 0.6153); Loss of stability (P = 0.629)",0,"T",-0.489,0,0,0,0.821
"6",19,"G19R","MAPT",4,"","17:44039758:G:A","P10636",137.414634146341,"Gain of solvent accessibility (P = 0.0456); Gain of MoRF binding (P = 0.0644); Loss of glycosylation at K24 (P = 0.0926); Loss of catalytic residue at L20 (P = 0.1423); Loss of methylation at K24 (P = 0.1742)",1.38629436111989,"G",-0.391,0,0,0,0.196
"7",19,"G19R","MAPT",4,"","17:44039758:G:C","P10636",137.414634146341,"Gain of solvent accessibility (P = 0.0456); Gain of MoRF binding (P = 0.0644); Loss of glycosylation at K24 (P = 0.0926); Loss of catalytic residue at L20 (P = 0.1423); Loss of methylation at K24 (P = 0.1742)",1.38629436111989,"G",-0.391,0,0,0,0.196
"8",21,"G21V","MAPT",3,"","17:44039765:G:T","P10636",98.4390243902439,"Loss of disorder (P = 0.0978); Loss of glycosylation at K24 (P = 0.1772); Loss of phosphorylation at T17 (P = 0.1993); Gain of catalytic residue at G21 (P = 0.3438); Gain of solvent accessibility (P = 0.3602)",1.09861228866811,"G",-0.573,0,0,0,0.644
"9",22,"D22N","MAPT",2,"","17:44039767:G:A","P10636",39.9756097560976,"Loss of solvent accessibility (P = 0.1202); Loss of glycosylation at K24 (P = 0.1604); Loss of relative solvent accessibility (P = 0.1807); Loss of stability (P = 0.1996); Loss of phosphorylation at T17 (P = 0.2205)",0.693147180559945,"D",-0.573,0,0,0,0.333
"10",27,"G27E","MAPT",9,"","17:44039783:G:A","P10636",10.7439024390244,"Gain of solvent accessibility (P = 0.012); Gain of relative solvent accessibility (P = 0.0479); Gain of glycosylation at T30 (P = 0.1208); Gain of phosphorylation at Y29 (P = 0.3154); Loss of catalytic residue at K24 (P = 0.3671)",2.19722457733622,"G",-0.661,0,0,0,-0.159
"11",30,"T30A","MAPT",8,"","17:44039791:A:G","P10636",88.6951219512195,"Gain of catalytic residue at T30 (P = 0.0361); Loss of glycosylation at T30 (P = 0.0649); Gain of phosphorylation at Y29 (P = 0.3204); Gain of MoRF binding (P = 0.6346); Loss of sheet (P = 0.6423)",2.07944154167984,"T",-0.687,0,0,0,-0.363
"12",36,"E36D","MAPT",3,"","17:44039811:G:T","P10636",30.2317073170732,"Gain of relative solvent accessibility (P = 0.2363); Loss of catalytic residue at E36 (P = 0.4216); Gain of solvent accessibility (P = 0.4496); Gain of glycosylation at T39 (P = 0.458); Loss of stability (P = 0.4664)",1.09861228866811,"E",-0.93,0,0,0,1.607
"13",36,"E36D","MAPT",3,"","17:44039811:G:C","P10636",30.2317073170732,"Gain of relative solvent accessibility (P = 0.2363); Loss of catalytic residue at E36 (P = 0.4216); Gain of solvent accessibility (P = 0.4496); Gain of glycosylation at T39 (P = 0.458); Loss of stability (P = 0.4664)",1.09861228866811,"E",-0.93,0,0,0,1.607
"14",39,"T39M","MAPT",3,"","17:44039819:C:T","P10636",1,"Loss of phosphorylation at T39 (P = 0.0141); Loss of glycosylation at T39 (P = 0.1546); Loss of methylation at K44 (P = 0.2417); Gain of ubiquitination at K44 (P = 0.4079); Gain of solvent accessibility (P = 0.5334)",1.09861228866811,"T",-0.815,0,0,0,2.425
"15",45,"E45V","MAPT",4,"","17:44049225:A:T","P10636",69.2073170731707,"Loss of solvent accessibility (P = 0.0052); Loss of relative solvent accessibility (P = 0.0404); Loss of glycosylation at K44 (P = 0.1626); Loss of phosphorylation at S46 (P = 0.1767); Gain of stability (P = 0.2909)",1.38629436111989,"E",-0.364,0,0,0,0.261
"16",47,"P47S","MAPT",1,"","17:44049230:C:T","P10636",59.4634146341463,"Gain of phosphorylation at P47 (P = 0.023); Gain of relative solvent accessibility (P = 0.09); Loss of glycosylation at T50 (P = 0.1265); Gain of solvent accessibility (P = 0.1903); Gain of catalytic residue at L43 (P = 0.2523)",0,"P",-0.239,0,0,0,0.247
"17",48,"L48V","MAPT",1,"","17:44049233:C:G","P10636",10.7439024390244,"Gain of glycosylation at S46 (P = 0.146); Loss of catalytic residue at L48 (P = 0.201); Gain of methylation at K44 (P = 0.3482); Loss of stability (P = 0.395); Loss of ubiquitination at K44 (P = 0.4035)",0,"L",-0.319,0,0,0,0.268
"18",52,"T52A","MAPT",1,"","17:44049245:A:G","P10636",20.4878048780488,"Loss of glycosylation at T52 (P = 0.0074); Loss of phosphorylation at T52 (P = 0.013); Loss of catalytic residue at L48 (P = 0.4931); Loss of stability (P = 0.6309); Loss of sheet (P = 0.6423)",0,"T",-0.575,0,0,0,0.175
"19",60,"G60V","MAPT",1,"","17:44049270:G:T","P10636",30.2317073170732,"Loss of relative solvent accessibility (P = 0.0404); Gain of glycosylation at T63 (P = 0.0848); Loss of solvent accessibility (P = 0.2668); Loss of phosphorylation at T63 (P = 0.5578); Gain of stability (P = 0.6106)",0,"G",-0.774,0,0,0,0.099
"20",67,"K67R","MAPT",1,"","17:44049291:A:G","P10636",108.182926829268,"Loss of ubiquitination at K67 (P = 0.0012); Loss of methylation at K67 (P = 0.0123); Loss of solvent accessibility (P = 0.1115); Loss of glycosylation at K67 (P = 0.1378); Loss of relative solvent accessibility (P = 0.1807)",0,"K",-0.514,0,0,0,-0.531
"21",69,"T69A","MAPT",2,"","17:44049296:A:G","P10636",20.4878048780488,"Loss of phosphorylation at T69 (P = 0.0064); Loss of glycosylation at T69 (P = 0.0112); Loss of methylation at K67 (P = 0.2501); Loss of stability (P = 0.3968); Gain of ubiquitination at K67 (P = 0.4036)",0.693147180559945,"T",-0.666,0,0,0,-0.704
"22",71,"T71R","MAPT",1,"","17:44049303:C:G","P10636",59.4634146341463,"Loss of phosphorylation at T71 (P = 0.0148); Loss of glycosylation at T71 (P = 0.0155); Loss of methylation at K67 (P = 0.0519); Gain of solvent accessibility (P = 0.2291); Gain of ubiquitination at K67 (P = 0.4036)",0,"T",-0.342,0,0,0,-0.718
"23",75,"V75A","MAPT",1,"","17:44051754:T:C","P10636",10.7439024390244,"Gain of relative solvent accessibility (P = 0.1571); Gain of glycosylation at T76 (P = 0.1803); Gain of solvent accessibility (P = 0.3956); Gain of phosphorylation at T71 (P = 0.5089); Loss of stability (P = 0.618)",0,"V",0.024,0.044,0,0.024,0.356
"24",76,"T76I","MAPT",6,"","17:44051757:C:T","P10636",156.90243902439,"Loss of phosphorylation at T76 (P = 0.015); Loss of glycosylation at T76 (P = 0.0255); Gain of catalytic residue at P78 (P = 0.0307); Loss of solvent accessibility (P = 0.5485); Loss of relative solvent accessibility (P = 0.5582)",1.79175946922805,"T",-0.113,0,0,0,-0.749
"25",76,"T76K","MAPT",6,"","17:44051757:C:A","P10636",166.646341463415,"Gain of ubiquitination at T76 (P = 0.0025); Gain of methylation at T76 (P = 0.0043); Loss of phosphorylation at T76 (P = 0.015); Gain of solvent accessibility (P = 0.0156); Gain of relative solvent accessibility (P = 0.0479)",1.79175946922805,"T",-0.113,0,0,0,-0.749
"26",78,"P78A","MAPT",2,"","17:44051762:C:G","P10636",117.926829268293,"Loss of solvent accessibility (P = 0.1322); Loss of relative solvent accessibility (P = 0.1807); Loss of stability (P = 0.2186); Gain of glycosylation at T76 (P = 0.2376); Loss of phosphorylation at T76 (P = 0.4686)",0.693147180559945,"P",-0.272,0,0,0,-0.45
"27",78,"P78T","MAPT",2,"","17:44051762:C:A","P10636",117.926829268293,"Gain of glycosylation at P78 (P = 0.0304); Gain of phosphorylation at P78 (P = 0.0545); Loss of stability (P = 0.1627); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.1922)",0.693147180559945,"P",-0.272,0,0,0,-0.45
"28",82,"E82D","MAPT",1,"","17:44051776:G:C","P10636",49.719512195122,"Loss of methylation at K87 (P = 0.128); Loss of solvent accessibility (P = 0.1813); Loss of glycosylation at K87 (P = 0.2757); Loss of stability (P = 0.3582); Loss of ubiquitination at K87 (P = 0.3786)",0,"E",-0.274,0,0,0,-0.607
"29",82,"E82D","MAPT",1,"","17:44051776:G:T","P10636",49.719512195122,"Loss of methylation at K87 (P = 0.128); Loss of solvent accessibility (P = 0.1813); Loss of glycosylation at K87 (P = 0.2757); Loss of stability (P = 0.3582); Loss of ubiquitination at K87 (P = 0.3786)",0,"E",-0.274,0,0,0,-0.607
"30",82,"E82K","MAPT",1,"","17:44051774:G:A","P10636",195.878048780488,"Gain of ubiquitination at E82 (P = 0.0018); Gain of methylation at E82 (P = 0.0093); Gain of glycosylation at E82 (P = 0.0173); Loss of stability (P = 0.1837); Loss of catalytic residue at D81 (P = 0.3096)",0,"E",-0.274,0,0,0,-0.607
"31",90,"A90V","MAPT",2,"","17:44051799:C:T","P10636",30.2317073170732,"Gain of methylation at K87 (P = 0.0692); Loss of phosphorylation at T95 (P = 0.193); Loss of glycosylation at K87 (P = 0.2202); Loss of ubiquitination at K87 (P = 0.3786); Gain of sheet (P = 0.6509)",0.693147180559945,"A",-0.536,0,0,0,0.052
"32",91,"A91V","MAPT",8,"","17:44051802:C:T","P10636",59.4634146341463,"Loss of relative solvent accessibility (P = 0.0404); Gain of methylation at K87 (P = 0.089); Loss of solvent accessibility (P = 0.1301); Loss of glycosylation at K87 (P = 0.1817); Loss of phosphorylation at T95 (P = 0.1849)",2.07944154167984,"A",-0.634,0,0,0,-0.628
"33",93,"P93L","MAPT",1,"","17:44051808:C:T","P10636",49.719512195122,"Loss of phosphorylation at T95 (P = 0.0932); Loss of glycosylation at T95 (P = 0.1079); Gain of catalytic residue at P93 (P = 0.3085); Gain of solvent accessibility (P = 0.571); Gain of sheet (P = 0.6509)",0,"P",-0.365,0,0,0,0.889
"34",102,"T102R","MAPT",1,"","17:44051835:C:G","P10636",117.926829268293,"Loss of glycosylation at T102 (P = 0.022); Loss of phosphorylation at T102 (P = 0.0651); Gain of solvent accessibility (P = 0.0808); Loss of catalytic residue at T102 (P = 0.1481); Gain of relative solvent accessibility (P = 0.2363)",0,"T",-0.383,0,0,0,-0.86
"35",107,"G107S","MAPT",1,"","17:44055752:G:A","P10636",69.2073170731707,"Gain of glycosylation at G107 (P = 0.0026); Gain of phosphorylation at G107 (P = 0.015); Loss of stability (P = 0.1459); Loss of catalytic residue at A106 (P = 0.1516); Gain of solvent accessibility (P = 0.3956)",0,"G",-0.421,0,0,0,-0.588
"36",107,"G107V","MAPT",9,"","17:44055753:G:T","P10636",127.670731707317,"Loss of catalytic residue at A106 (P = 0.1576); Loss of phosphorylation at T102 (P = 0.2096); Loss of glycosylation at T102 (P = 0.2467); Loss of stability (P = 0.5525); Loss of relative solvent accessibility (P = 0.5582)",2.19722457733622,"G",-0.421,0,0,0,-0.588
"37",116,"D116E","MAPT",3,"","17:44055781:C:G","P10636",59.4634146341463,"Loss of glycosylation at S113 (P = 0.1671); Gain of phosphorylation at S113 (P = 0.2724); Gain of solvent accessibility (P = 0.3089); Loss of catalytic residue at H121 (P = 0.5061); Gain of sheet (P = 0.6509)",1.09861228866811,"D",-0.519,0,0,0,-0.752
"38",116,"D116E","MAPT",3,"","17:44055781:C:A","P10636",59.4634146341463,"Loss of glycosylation at S113 (P = 0.1671); Gain of phosphorylation at S113 (P = 0.2724); Gain of solvent accessibility (P = 0.3089); Loss of catalytic residue at H121 (P = 0.5061); Gain of sheet (P = 0.6509)",1.09861228866811,"D",-0.519,0,0,0,-0.752
"39",125,"E125K","MAPT",1,"","17:44055806:G:A","P10636",117.926829268293,"Gain of ubiquitination at E125 (P = 9e-04); Gain of methylation at E125 (P = 0.0252); Gain of glycosylation at E125 (P = 0.0342); Gain of relative solvent accessibility (P = 0.0999); Gain of solvent accessibility (P = 0.1045)",0,"E",-0.571,0,0,0,0.101
"40",126,"P126S","MAPT",6,"","17:44060546:C:T","P10636",147.158536585366,"Gain of phosphorylation at P126 (P = 0.0388); Loss of glycosylation at T123 (P = 0.0516); Gain of relative solvent accessibility (P = 0.2629); Loss of methylation at K130 (P = 0.312); Gain of ubiquitination at K130 (P = 0.3527)",1.79175946922805,"P",-0.378,0,0,0,0.618
"41",137,"L137P","MAPT",3,"","17:44060580:T:C","P10636",117.926829268293,"Gain of glycosylation at L137 (P = 0.0382); Gain of relative solvent accessibility (P = 0.0479); Loss of stability (P = 0.0616); Gain of solvent accessibility (P = 0.1376); Gain of catalytic residue at L137 (P = 0.3359)",1.09861228866811,"L",-0.21,0,0,0,0.124
"42",166,"A166V","MAPT",1,"","17:44060667:C:T","P10636",88.6951219512195,"Loss of glycosylation at T167 (P = 0.1428); Loss of methylation at R164 (P = 0.4053); Gain of solvent accessibility (P = 0.5334); Loss of phosphorylation at S171 (P = 0.6134); Gain of MoRF binding (P = 0.7468)",0,"A",-0.748,0,0,0,-0.155
"43",168,"R168C","MAPT",3,"","17:44060672:C:T","P10636",147.158536585366,"Loss of phosphorylation at S171 (P = 0.0775); Loss of catalytic residue at R168 (P = 0.0837); Gain of glycosylation at T167 (P = 0.112); Loss of solvent accessibility (P = 0.3854); Gain of methylation at R164 (P = 0.4204)",1.09861228866811,"R",-0.634,0,0,0,2.537
"44",177,"D177N","MAPT",1,"","17:44060699:G:A","P10636",108.182926829268,"Loss of solvent accessibility (P = 0.1202); Loss of relative solvent accessibility (P = 0.1807); Gain of glycosylation at T178 (P = 0.2384); Gain of catalytic residue at D177 (P = 0.2746); Gain of methylation at R182 (P = 0.4144)",0,"D",-0.79,0,0,0,-0.338
"45",177,"D177V","MAPT",13,"","17:44060700:A:T","P10636",108.182926829268,"Loss of solvent accessibility (P = 0.0544); Loss of relative solvent accessibility (P = 0.0981); Gain of glycosylation at T178 (P = 0.144); Gain of catalytic residue at E176 (P = 0.3132); Gain of methylation at R182 (P = 0.3623)",2.56494935746154,"D",-0.79,0,0,0,-0.338
"46",181,"G181S","MAPT",1,"","17:44060711:G:A","P10636",108.182926829268,"Gain of phosphorylation at G181 (P = 0.0146); Gain of glycosylation at G181 (P = 0.0648); Loss of relative solvent accessibility (P = 0.0981); Loss of stability (P = 0.3729); Loss of solvent accessibility (P = 0.3854)",0,"G",-0.904,0,0,0,0.24
"47",184,"A184T","MAPT",2,"","17:44060720:G:A","P10636",88.6951219512195,"Gain of phosphorylation at A184 (P = 0.0111); Gain of methylation at K189 (P = 0.1037); Loss of glycosylation at K189 (P = 0.1968); Gain of ubiquitination at K189 (P = 0.3023); Gain of catalytic residue at A184 (P = 0.41)",0.693147180559945,"A",-0.428,0,0,0,2.688
"48",195,"D195G","MAPT",1,"","17:44060754:A:G","P10636",283.573170731707,"Gain of helix (P = 0.0022); Loss of loop (P = 0.0022); Loss of solvent accessibility (P = 0.0674); Loss of stability (P = 0.1446); Gain of catalytic residue at L196 (P = 0.2532)",0,"D",-0.428,0,0,0,1.712
"49",197,"H197Q","MAPT",1,"","17:44060761:C:G","P10636",137.414634146341,"Loss of catalytic residue at L196 (P = 0.2224); Gain of glycosylation at P201 (P = 0.2469); Gain of MoRF binding (P = 0.5396); Gain of solvent accessibility (P = 0.5485); Loss of stability (P = 0.5995)",0,"H",-0.283,0,0,0,2.513
"50",197,"H197Q","MAPT",1,"","17:44060761:C:A","P10636",137.414634146341,"Loss of catalytic residue at L196 (P = 0.2224); Gain of glycosylation at P201 (P = 0.2469); Gain of MoRF binding (P = 0.5396); Gain of solvent accessibility (P = 0.5485); Loss of stability (P = 0.5995)",0,"H",-0.283,0,0,0,2.513
"51",200,"G200A","MAPT",4,"","17:44060769:G:C","P10636",98.4390243902439,"Loss of catalytic residue at G200 (P = 0.2691); Loss of glycosylation at K204 (P = 0.2791); Gain of ubiquitination at K204 (P = 0.3757); Loss of methylation at K204 (P = 0.4366); Gain of solvent accessibility (P = 0.5093)",1.38629436111989,"G",-0.493,0,0,0,0.491
"52",200,"G200E","MAPT",4,"","17:44060769:G:A","P10636",156.90243902439,"Gain of solvent accessibility (P = 0.0026); Gain of relative solvent accessibility (P = 0.0166); Gain of glycosylation at P201 (P = 0.2128); Loss of catalytic residue at E199 (P = 0.3416); Gain of ubiquitination at K204 (P = 0.3757)",1.38629436111989,"G",-0.493,0,0,0,0.491
"53",200,"G200W","MAPT",2,"","17:44060768:G:T","P10636",137.414634146341,"Loss of glycosylation at K204 (P = 0.2595); Loss of ubiquitination at K204 (P = 0.3654); Gain of MoRF binding (P = 0.3772); Gain of methylation at K204 (P = 0.4499); Loss of catalytic residue at L203 (P = 0.4973)",0.693147180559945,"G",-0.493,0,0,0,0.491
"54",202,"P202Q","MAPT",17431,"","17:44060775:C:A","P10636",429.731707317073,"Loss of glycosylation at P201 (P = 0.1774); Loss of catalytic residue at P201 (P = 0.2509); Gain of solvent accessibility (P = 0.3418); Loss of ubiquitination at K204 (P = 0.3501); Gain of MoRF binding (P = 0.376)",9.76600550921487,"P",-0.503,0,0,0,2.174
"55",203,"L203P","MAPT",1,"","17:44060778:T:C","P10636",225.109756097561,"Gain of relative solvent accessibility (P = 0.0249); Gain of helix (P = 0.0349); Gain of glycosylation at L203 (P = 0.0443); Gain of catalytic residue at P202 (P = 0.0519); Loss of loop (P = 0.0603)",0,"L",-0.458,0,0,0,2.539
"56",204,"K204Q","MAPT",1,"","17:44060780:A:C","P10636",264.085365853659,"Loss of ubiquitination at K204 (P = 0.0023); Loss of methylation at K204 (P = 0.0031); Loss of glycosylation at K204 (P = 0.0194); Loss of solvent accessibility (P = 0.0561); Loss of relative solvent accessibility (P = 0.1807)",0,"K",-0.431,0,0,0,0.349
"57",205,"G205W","MAPT",2,"","17:44060783:G:T","P10636",283.573170731707,"Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at K204 (P = 0.0988); Gain of catalytic residue at L203 (P = 0.1365); Gain of ubiquitination at K209 (P = 0.3433); Gain of MoRF binding (P = 0.3557)",0.693147180559945,"G",-0.431,0,0,0,1.642
"58",209,"K209R","MAPT",1,"","17:44060796:A:G","P10636",225.109756097561,"Loss of ubiquitination at K209 (P = 0.0039); Loss of methylation at K209 (P = 0.0169); Loss of glycosylation at K209 (P = 0.0391); Gain of stability (P = 0.3568); Gain of solvent accessibility (P = 0.4067)",0,"K",-0.665,0,0,0,-0.234
"59",213,"G213R","MAPT",466,"","17:44060807:G:C","P10636",244.59756097561,"Gain of solvent accessibility (P = 0.0037); Loss of methylation at K215 (P = 0.0468); Loss of glycosylation at K215 (P = 0.0635); Gain of ubiquitination at K209 (P = 0.3459); Gain of MoRF binding (P = 0.3944)",6.14418563412565,"G",-0.677,0,0,0,1.07
"60",217,"E217V","MAPT",1,"","17:44060820:A:T","P10636",225.109756097561,"Gain of glycosylation at S214 (P = 0.0589); Loss of solvent accessibility (P = 0.1986); Gain of methylation at K215 (P = 0.2257); Gain of ubiquitination at K215 (P = 0.3565); Loss of relative solvent accessibility (P = 0.3919)",0,"E",-0.877,0,0,0,0.242
"61",222,"R222C","MAPT",30,"","17:44060834:C:T","P10636",273.829268292683,"Gain of catalytic residue at V224 (P = 0.0626); Gain of glycosylation at S227 (P = 0.1553); Loss of solvent accessibility (P = 0.1744); Loss of stability (P = 0.2382); Loss of relative solvent accessibility (P = 0.5582)",3.40119738166216,"R",-0.902,0,0,0,-0.368
"62",223,"D223N","MAPT",5,"","17:44060837:G:A","P10636",69.2073170731707,"Loss of stability (P = 0.1812); Loss of glycosylation at S228 (P = 0.2653); Gain of methylation at R222 (P = 0.6599); Loss of phosphorylation at S227 (P = 0.7447); Gain of MoRF binding (P = 0.8691)",1.6094379124341,"D",-0.801,0,0,0,-0.608
"63",225,"D225N","MAPT",2,"","17:44060843:G:A","P10636",176.390243902439,"Gain of glycosylation at S228 (P = 0.2879); Loss of stability (P = 0.3151); Gain of catalytic residue at D225 (P = 0.3717); Loss of solvent accessibility (P = 0.6392); Gain of methylation at R222 (P = 0.6551)",0.693147180559945,"D",-0.921,0,0,0,-0.898
"64",228,"S228F","MAPT",2,"","17:44060853:C:T","P10636",283.573170731707,"Loss of phosphorylation at S228 (P = 0.0013); Loss of glycosylation at S228 (P = 0.0526); Loss of relative solvent accessibility (P = 0.5582); Loss of solvent accessibility (P = 0.6498); Gain of sheet (P = 0.6509)",0.693147180559945,"S",-0.737,0,0,0,-0.293
"65",232,"S232C","MAPT",2,"","17:44060865:C:G","P10636",176.390243902439,"Loss of phosphorylation at S232 (P = 0.0015); Loss of glycosylation at S232 (P = 0.0211); Gain of catalytic residue at S232 (P = 0.073); Loss of methylation at K236 (P = 0.2331); Gain of ubiquitination at K236 (P = 0.2713)",0.693147180559945,"S",-0.565,0,0,0,-0.512
"66",232,"S232F","MAPT",2,"","17:44060865:C:T","P10636",166.646341463415,"Loss of phosphorylation at S232 (P = 0.0015); Loss of glycosylation at S232 (P = 0.0211); Gain of ubiquitination at K236 (P = 0.2483); Loss of methylation at K236 (P = 0.2521); Loss of MoRF binding (P = 0.8489)",0.693147180559945,"S",-0.565,0,0,0,-0.512
"67",233,"P233R","MAPT",1,"","17:44060868:C:G","P10636",186.134146341463,"Loss of glycosylation at P233 (P = 0.0326); Gain of solvent accessibility (P = 0.0789); Loss of catalytic residue at P233 (P = 0.1666); Gain of methylation at K236 (P = 0.2088); Gain of relative solvent accessibility (P = 0.2363)",0,"P",-0.565,0,0,0,0.665
"68",236,"K236E","MAPT",2,"","17:44060876:A:G","P10636",244.59756097561,"Loss of ubiquitination at K236 (P = 0.0067); Loss of methylation at K236 (P = 0.0087); Loss of glycosylation at K236 (P = 0.099); Gain of relative solvent accessibility (P = 0.1571); Loss of catalytic residue at K236 (P = 0.1785)",0.693147180559945,"K",-0.541,0,0,0,0.251
"69",237,"A237T","MAPT",2,"","17:44060879:G:A","P10636",225.109756097561,"Gain of phosphorylation at A237 (P = 0.0065); Gain of glycosylation at A237 (P = 0.0157); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.1301); Gain of methylation at K236 (P = 0.2146)",0.693147180559945,"A",-0.541,0,0,0,1.84
"70",242,"D242G","MAPT",1,"","17:44060895:A:G","P10636",49.719512195122,"Loss of solvent accessibility (P = 0.0477); Gain of glycosylation at P245 (P = 0.1257); Gain of methylation at R244 (P = 0.1611); Loss of relative solvent accessibility (P = 0.1807); Gain of catalytic residue at G243 (P = 0.2744)",0,"D",-0.676,0,0,0,1.418
"71",243,"G243R","MAPT",1,"","17:44060897:G:C","P10636",147.158536585366,"Gain of solvent accessibility (P = 0.019); Gain of glycosylation at P245 (P = 0.0542); Loss of catalytic residue at P239 (P = 0.0914); Loss of methylation at R244 (P = 0.2792); Gain of MoRF binding (P = 0.3095)",0,"G",-0.688,0,0,0,1.464
"72",243,"G243R","MAPT",1,"","17:44060897:G:A","P10636",147.158536585366,"Gain of solvent accessibility (P = 0.019); Gain of glycosylation at P245 (P = 0.0542); Loss of catalytic residue at P239 (P = 0.0914); Loss of methylation at R244 (P = 0.2792); Gain of MoRF binding (P = 0.3095)",0,"G",-0.688,0,0,0,1.464
"73",244,"R244L","MAPT",4,"","17:44060901:G:T","P10636",137.414634146341,"Gain of glycosylation at T248 (P = 0.1379); Loss of methylation at R244 (P = 0.1946); Gain of catalytic residue at R244 (P = 0.201); Loss of solvent accessibility (P = 0.3103); Loss of MoRF binding (P = 0.5475)",1.38629436111989,"R",-0.664,0,0,0,0.986
"74",248,"T248R","MAPT",1,"","17:44060913:C:G","P10636",137.414634146341,"Loss of phosphorylation at T248 (P = 0.0023); Loss of glycosylation at T248 (P = 0.0308); Gain of solvent accessibility (P = 0.0503); Gain of MoRF binding (P = 0.1103); Loss of methylation at R244 (P = 0.3682)",0,"T",-0.599,0,0,0,0.671
"75",257,"P257A","MAPT",1,"","17:44060939:C:G","P10636",205.621951219512,"Loss of glycosylation at T254 (P = 0.0947); Loss of stability (P = 0.1189); Loss of solvent accessibility (P = 0.1322); Loss of relative solvent accessibility (P = 0.1807); Loss of phosphorylation at S255 (P = 0.2339)",0,"P",-0.089,0,0,0,2.545
"76",261,"A261V","MAPT",3,"","17:44060952:C:T","P10636",108.182926829268,"Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.2517); Gain of catalytic residue at A261 (P = 0.4116); Loss of disorder (P = 0.5951); Loss of glycosylation at P257 (P = 0.6194)",1.09861228866811,"A",0.167,0.837,0.167,0.147,0.855
"77",262,"E262G","MAPT",1,"","17:44060955:A:G","P10636",176.390243902439,"Loss of solvent accessibility (P = 0.0187); Gain of catalytic residue at A261 (P = 0.088); Loss of stability (P = 0.0949); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at P257 (P = 0.6425)",0,"E",0.127,0.837,0.167,0.147,2.233
"78",266,"P266T","MAPT",1,"","17:44060966:C:A","P10636",205.621951219512,"Loss of catalytic residue at L267 (P = 0.2168); Gain of phosphorylation at P266 (P = 0.2524); Loss of disorder (P = 0.303); Gain of glycosylation at P266 (P = 0.3518); Loss of relative solvent accessibility (P = 0.5582)",0,"P",0.184,0,0,0,0.006
"79",267,"L267V","MAPT",1,"","17:44060969:C:G","P10636",98.4390243902439,"Loss of catalytic residue at L267 (P = 0.1113); Loss of stability (P = 0.4986); Gain of disorder (P = 0.5645); Loss of sheet (P = 0.6423); Gain of MoRF binding (P = 0.8504)",0,"L",0.313,0.333,0,0.313,0.537
"80",273,"S273A","MAPT",4,"","17:44060987:T:G","P10636",127.670731707317,"Loss of glycosylation at S273 (P = 0.0281); Loss of phosphorylation at S273 (P = 0.0923); Loss of disorder (P = 0.1791); Loss of stability (P = 0.1875); Loss of methylation at K274 (P = 0.1956)",1.38629436111989,"S",0.097,2.652,0.295,0.275,0.77
"81",273,"S273F","MAPT",1,"","17:44060988:C:T","P10636",195.878048780488,"Loss of glycosylation at S273 (P = 0.0281); Loss of disorder (P = 0.0351); Gain of methylation at K274 (P = 0.0726); Loss of phosphorylation at S273 (P = 0.0923); Loss of relative solvent accessibility (P = 0.0981)",0,"S",0.097,2.652,0.295,0.275,0.77
"82",273,"S273P","MAPT",4,"","17:44060987:T:C","P10636",78.9512195121951,"Loss of glycosylation at S273 (P = 0.0453); Loss of stability (P = 0.0785); Loss of phosphorylation at S273 (P = 0.0923); Gain of methylation at K274 (P = 0.1154); Gain of catalytic residue at L272 (P = 0.2005)",1.38629436111989,"S",0.097,2.652,0.295,0.275,0.77
"83",280,"P280A","MAPT",1,"","17:44061008:C:G","P10636",137.414634146341,"Loss of glycosylation at T277 (P = 0.0601); Loss of disorder (P = 0.1501); Loss of phosphorylation at T277 (P = 0.1697); Gain of catalytic residue at D285 (P = 0.4101); Loss of stability (P = 0.5542)",0,"P",-0.245,0,0,0,2.306
"84",285,"D285E","MAPT",14849,"","17:44061025:C:G","P10636",117.926829268293,"Gain of glycosylation at P284 (P = 0.095); Gain of solvent accessibility (P = 0.2601); Gain of catalytic residue at D285 (P = 0.3212); Gain of phosphorylation at S282 (P = 0.3588); Gain of disorder (P = 0.4968)",9.60568780189606,"D",-0.395,0,0,0,2.704
"85",285,"D285E","MAPT",14849,"","17:44061025:C:A","P10636",117.926829268293,"Gain of glycosylation at P284 (P = 0.095); Gain of solvent accessibility (P = 0.2601); Gain of catalytic residue at D285 (P = 0.3212); Gain of phosphorylation at S282 (P = 0.3588); Gain of disorder (P = 0.4968)",9.60568780189606,"D",-0.395,0,0,0,2.704
"86",286,"G286R","MAPT",1,"","17:44061026:G:A","P10636",127.670731707317,"Loss of glycosylation at S282 (P = 0.0846); Gain of solvent accessibility (P = 0.1319); Loss of phosphorylation at S282 (P = 0.2806); Loss of catalytic residue at G286 (P = 0.2913); Loss of methylation at R291 (P = 0.3238)",0,"G",-0.478,0,0,0,1.689
"87",286,"G286R","MAPT",1,"","17:44061026:G:C","P10636",127.670731707317,"Loss of glycosylation at S282 (P = 0.0846); Gain of solvent accessibility (P = 0.1319); Loss of phosphorylation at S282 (P = 0.2806); Loss of catalytic residue at G286 (P = 0.2913); Loss of methylation at R291 (P = 0.3238)",0,"G",-0.478,0,0,0,1.689
"88",287,"P287L","MAPT",1,"","17:44061030:C:T","P10636",127.670731707317,"Loss of disorder (P = 0.0753); Loss of glycosylation at S288 (P = 0.0949); Gain of catalytic residue at P287 (P = 0.1806); Loss of phosphorylation at S282 (P = 0.1957); Gain of methylation at R291 (P = 0.2334)",0,"P",-0.478,0,0,0,0.928
"89",287,"P287S","MAPT",1,"","17:44061029:C:T","P10636",98.4390243902439,"Gain of glycosylation at P287 (P = 0.0317); Gain of phosphorylation at P287 (P = 0.0339); Gain of methylation at R291 (P = 0.3123); Loss of stability (P = 0.323); Gain of disorder (P = 0.4926)",0,"P",-0.478,0,0,0,0.928
"90",290,"G290R","MAPT",1,"","17:44061038:G:C","P10636",186.134146341463,"Gain of solvent accessibility (P = 0.0037); Loss of ubiquitination at K293 (P = 0.1041); Gain of methylation at K293 (P = 0.1582); Loss of glycosylation at S288 (P = 0.1871); Loss of catalytic residue at R291 (P = 0.3107)",0,"G",-0.538,0,0,0,1.007
"91",290,"G290R","MAPT",1,"","17:44061038:G:A","P10636",186.134146341463,"Gain of solvent accessibility (P = 0.0037); Loss of ubiquitination at K293 (P = 0.1041); Gain of methylation at K293 (P = 0.1582); Loss of glycosylation at S288 (P = 0.1871); Loss of catalytic residue at R291 (P = 0.3107)",0,"G",-0.538,0,0,0,1.007
"92",291,"R291W","MAPT",10,"","17:44061041:C:T","P10636",264.085365853659,"Loss of solvent accessibility (P = 0.0087); Loss of disorder (P = 0.0149); Gain of methylation at K293 (P = 0.089); Loss of phosphorylation at S288 (P = 0.0958); Loss of relative solvent accessibility (P = 0.0981)",2.30258509299405,"R",-0.538,0,0,0,2.67
"93",293,"K293E","MAPT",1,"","17:44061047:A:G","P10636",117.926829268293,"Loss of ubiquitination at K293 (P = 0.0047); Loss of methylation at K293 (P = 0.064); Loss of glycosylation at K293 (P = 0.0907); Gain of relative solvent accessibility (P = 0.1571); Gain of disorder (P = 0.1777)",0,"K",-0.492,0,0,0,0.066
"94",297,"A297G","MAPT",5,"","17:44061060:C:G","P10636",156.90243902439,"Loss of stability (P = 0.0889); Gain of disorder (P = 0.124); Gain of catalytic residue at A297 (P = 0.1472); Gain of methylation at K293 (P = 0.2323); Gain of ubiquitination at K293 (P = 0.3247)",1.6094379124341,"A",-0.307,0,0,0,1.208
"95",300,"E300A","MAPT",1,"","17:44061069:A:C","P10636",332.292682926829,"Loss of solvent accessibility (P = 0.0053); Loss of catalytic residue at E300 (P = 0.0494); Loss of disorder (P = 0.0637); Loss of relative solvent accessibility (P = 0.0676); Loss of stability (P = 0.344)",0,"E",0.04,1.902,0.211,0.191,0.224
"96",302,"T302M","MAPT",1,"","17:44061075:C:T","P10636",244.59756097561,"Loss of disorder (P = 0.1332); Loss of glycosylation at T302 (P = 0.3172); Loss of relative solvent accessibility (P = 0.3219); Loss of phosphorylation at T302 (P = 0.4302); Loss of solvent accessibility (P = 0.5185)",0,"T",0.356,1.902,0.211,0.191,0.511
"97",303,"F303L","MAPT",1,"","17:44061079:T:G","P10636",117.926829268293,"Loss of stability (P = 0.1638); Gain of disorder (P = 0.1952); Gain of glycosylation at T308 (P = 0.2995); Gain of phosphorylation at T308 (P = 0.3201); Gain of catalytic residue at F303 (P = 0.4994)",0,"F",0.345,1.902,0.211,0.191,0.454
"98",303,"F303L","MAPT",1,"","17:44061077:T:C","P10636",117.926829268293,"Loss of stability (P = 0.1638); Gain of disorder (P = 0.1952); Gain of glycosylation at T308 (P = 0.2995); Gain of phosphorylation at T308 (P = 0.3201); Gain of catalytic residue at F303 (P = 0.4994)",0,"F",0.345,1.902,0.211,0.191,0.454
"99",303,"F303L","MAPT",1,"","17:44061079:T:A","P10636",117.926829268293,"Loss of stability (P = 0.1638); Gain of disorder (P = 0.1952); Gain of glycosylation at T308 (P = 0.2995); Gain of phosphorylation at T308 (P = 0.3201); Gain of catalytic residue at F303 (P = 0.4994)",0,"F",0.345,1.902,0.211,0.191,0.454
"100",305,"V305G","MAPT",1,"","17:44061084:T:G","P10636",166.646341463415,"Gain of disorder (P = 0.0392); Loss of stability (P = 0.0428); Loss of glycosylation at T308 (P = 0.1151); Gain of phosphorylation at T308 (P = 0.1357); Gain of relative solvent accessibility (P = 0.1571)",0,"V",0.101,1.902,0.211,0.191,0.087
"101",305,"V305M","MAPT",3,"","17:44061083:G:A","P10636",127.670731707317,"Loss of relative solvent accessibility (P = 0.0981); Gain of disorder (P = 0.1146); Loss of solvent accessibility (P = 0.1362); Gain of catalytic residue at H304 (P = 0.2081); Loss of glycosylation at T308 (P = 0.3019)",1.09861228866811,"V",0.101,1.902,0.211,0.191,0.087
"102",306,"E306A","MAPT",1,"","17:44061087:A:C","P10636",186.134146341463,"Loss of solvent accessibility (P = 0.0721); Loss of disorder (P = 0.0786); Loss of catalytic residue at E306 (P = 0.1199); Loss of glycosylation at T308 (P = 0.2872); Loss of phosphorylation at T308 (P = 0.3153)",0,"E",0.374,1.902,0.211,0.191,-0.535
"103",309,"P309S","MAPT",1,"","17:44061095:C:T","P10636",127.670731707317,"Gain of glycosylation at P309 (P = 0.0648); Loss of catalytic residue at P309 (P = 0.1718); Loss of phosphorylation at T308 (P = 0.1943); Loss of stability (P = 0.1969); Loss of methylation at K313 (P = 0.2208)",0,"P",-0.255,0,0,0,0.174
"104",311,"V311M","MAPT",4,"","17:44061101:G:A","P10636",20.4878048780488,"Gain of disorder (P = 0.2525); Gain of ubiquitination at K313 (P = 0.2682); Gain of glycosylation at K313 (P = 0.2797); Gain of methylation at K313 (P = 0.319); Loss of phosphorylation at T308 (P = 0.3485)",1.38629436111989,"V",-0.421,0,0,0,1.478
"105",312,"Q312P","MAPT",1,"","17:44061105:A:C","P10636",176.390243902439,"Gain of glycosylation at Q312 (P = 0.0427); Gain of catalytic residue at N310 (P = 0.1273); Gain of phosphorylation at T308 (P = 0.1786); Gain of disorder (P = 0.2573); Gain of ubiquitination at K313 (P = 0.2754)",0,"Q",-0.387,0,0,0,0.967
"106",313,"K313N","MAPT",3,"","17:44061109:G:C","P10636",166.646341463415,"Loss of ubiquitination at K313 (P = 0.0059); Loss of methylation at K313 (P = 0.007); Loss of solvent accessibility (P = 0.0371); Loss of glycosylation at K313 (P = 0.1426); Loss of phosphorylation at S318 (P = 0.1733)",1.09861228866811,"K",-0.579,0,0,0,1.184
"107",313,"K313N","MAPT",3,"","17:44061109:G:T","P10636",166.646341463415,"Loss of ubiquitination at K313 (P = 0.0059); Loss of methylation at K313 (P = 0.007); Loss of solvent accessibility (P = 0.0371); Loss of glycosylation at K313 (P = 0.1426); Loss of phosphorylation at S318 (P = 0.1733)",1.09861228866811,"K",-0.579,0,0,0,1.184
"108",316,"A316G","MAPT",2,"","17:44061117:C:G","P10636",59.4634146341463,"Gain of relative solvent accessibility (P = 0.09); Loss of stability (P = 0.1789); Gain of phosphorylation at S318 (P = 0.2102); Gain of ubiquitination at K313 (P = 0.2182); Gain of methylation at K313 (P = 0.2982)",0.693147180559945,"A",-0.766,0,0,0,0.941
"109",316,"A316V","MAPT",2,"","17:44061117:C:T","P10636",39.9756097560976,"Loss of ubiquitination at K313 (P = 0.0756); Loss of phosphorylation at S318 (P = 0.1905); Gain of catalytic residue at E319 (P = 0.2031); Gain of methylation at K313 (P = 0.2915); Loss of disorder (P = 0.3313)",0.693147180559945,"A",-0.766,0,0,0,0.941
"110",325,"A325T","MAPT",1,"","17:44061143:G:A","P10636",59.4634146341463,"Gain of glycosylation at A325 (P = 0.0153); Gain of phosphorylation at A325 (P = 0.0449); Gain of solvent accessibility (P = 0.28); Loss of methylation at R324 (P = 0.3711); Loss of stability (P = 0.4356)",0,"A",-0.188,0,0,0,0.518
"111",326,"A326T","MAPT",1,"","17:44061146:G:A","P10636",88.6951219512195,"Gain of phosphorylation at A326 (P = 0.0164); Gain of glycosylation at A326 (P = 0.0334); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.1986); Loss of stability (P = 0.2236)",0,"A",-0.09,0,0,0,1.361
"112",331,"P331S","MAPT",1,"","17:44061161:C:T","P10636",137.414634146341,"Gain of glycosylation at P331 (P = 0.0182); Gain of phosphorylation at P331 (P = 0.0226); Loss of relative solvent accessibility (P = 0.107); Loss of solvent accessibility (P = 0.1279); Gain of catalytic residue at E333 (P = 0.4554)",0,"P",-0.341,0,0,0,0.824
"113",334,"G334E","MAPT",7,"","17:44061171:G:A","P10636",117.926829268293,"Gain of glycosylation at P335 (P = 0.1276); Loss of catalytic residue at G334 (P = 0.1655); Gain of solvent accessibility (P = 0.2192); Loss of methylation at R338 (P = 0.2854); Gain of stability (P = 0.8311)",1.94591014905531,"G",-0.631,0,0,0,0.844
"114",335,"P335A","MAPT",1,"","17:44061173:C:G","P10636",69.2073170731707,"Loss of catalytic residue at P335 (P = 0.1115); Loss of glycosylation at P335 (P = 0.1528); Gain of methylation at R338 (P = 0.1585); Loss of solvent accessibility (P = 0.5743); Gain of MoRF binding (P = 0.7901)",0,"P",-0.613,0,0,0,2.558
"115",335,"P335Q","MAPT",1,"","17:44061174:C:A","P10636",78.9512195121951,"Loss of catalytic residue at P335 (P = 0.0747); Loss of glycosylation at P335 (P = 0.1528); Loss of relative solvent accessibility (P = 0.1807); Loss of methylation at R338 (P = 0.2412); Loss of solvent accessibility (P = 0.3473)",0,"P",-0.613,0,0,0,2.558
"116",339,"G339A","MAPT",1,"","17:44061186:G:C","P10636",69.2073170731707,"Loss of catalytic residue at P335 (P = 0.0775); Loss of relative solvent accessibility (P = 0.0981); Loss of methylation at R338 (P = 0.2641); Gain of glycosylation at S341 (P = 0.3096); Loss of solvent accessibility (P = 0.3368)",0,"G",-0.481,0,0,0,1.517
"117",346,"T346A","MAPT",2,"","17:44061206:A:G","P10636",30.2317073170732,"Loss of phosphorylation at T346 (P = 0.0093); Loss of glycosylation at T346 (P = 0.0761); Loss of methylation at K347 (P = 0.2073); Loss of ubiquitination at K347 (P = 0.4093); Loss of solvent accessibility (P = 0.4995)",0.693147180559945,"T",-0.517,0,0,0,0.676
"118",348,"E348D","MAPT",2,"","17:44061214:G:C","P10636",30.2317073170732,"Loss of methylation at K347 (P = 0.1956); Loss of glycosylation at K347 (P = 0.1987); Loss of ubiquitination at K347 (P = 0.4033); Loss of solvent accessibility (P = 0.5485); Gain of catalytic residue at K347 (P = 0.6101)",0.693147180559945,"E",-0.775,0,0,0,0.841
"119",348,"E348D","MAPT",2,"","17:44061214:G:T","P10636",30.2317073170732,"Loss of methylation at K347 (P = 0.1956); Loss of glycosylation at K347 (P = 0.1987); Loss of ubiquitination at K347 (P = 0.4033); Loss of solvent accessibility (P = 0.5485); Gain of catalytic residue at K347 (P = 0.6101)",0.693147180559945,"E",-0.775,0,0,0,0.841
"120",355,"S355C","MAPT",3,"","17:44061234:C:G","P10636",108.182926829268,"Loss of phosphorylation at S355 (P = 0.0069); Gain of catalytic residue at P354 (P = 0.0073); Loss of glycosylation at S355 (P = 0.0363); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.086)",1.09861228866811,"S",-0.616,0,0,0,0.253
"121",355,"S355F","MAPT",3,"","17:44061234:C:T","P10636",156.90243902439,"Loss of phosphorylation at S355 (P = 0.0069); Loss of relative solvent accessibility (P = 0.0186); Loss of glycosylation at S355 (P = 0.0363); Loss of solvent accessibility (P = 0.045); Gain of catalytic residue at S355 (P = 0.0645)",1.09861228866811,"S",-0.616,0,0,0,0.253
"122",355,"S355P","MAPT",1,"","17:44061233:T:C","P10636",127.670731707317,"Loss of phosphorylation at S355 (P = 0.0069); Gain of catalytic residue at P354 (P = 0.0168); Gain of sheet (P = 0.0507); Loss of loop (P = 0.0603); Gain of glycosylation at S355 (P = 0.1106)",0,"S",-0.616,0,0,0,0.253
"123",357,"K357E","MAPT",2,"","17:44061239:A:G","P10636",127.670731707317,"Loss of ubiquitination at K357 (P = 0.0043); Loss of methylation at K357 (P = 0.0087); Loss of glycosylation at K357 (P = 0.0326); Loss of MoRF binding (P = 0.0726); Gain of helix (P = 0.0893)",0.693147180559945,"K",-0.581,0,0,0,-0.301
"124",363,"P363L","MAPT",1,"","17:44061258:C:T","P10636",127.670731707317,"Loss of methylation at K366 (P = 0.0548); Gain of MoRF binding (P = 0.0551); Loss of glycosylation at P363 (P = 0.098); Loss of ubiquitination at K366 (P = 0.1062); Gain of catalytic residue at K366 (P = 0.4592)",0,"P",-0.314,0,0,0,1.159
"125",363,"P363S","MAPT",1,"","17:44061257:C:T","P10636",98.4390243902439,"Gain of phosphorylation at P363 (P = 0.0081); Gain of MoRF binding (P = 0.0477); Loss of methylation at K366 (P = 0.0696); Loss of ubiquitination at K366 (P = 0.1216); Loss of stability (P = 0.286)",0,"P",-0.314,0,0,0,1.159
"126",364,"R364P","MAPT",4,"","17:44061261:G:C","P10636",195.878048780488,"Loss of MoRF binding (P = 0.0107); Gain of glycosylation at R364 (P = 0.0113); Gain of catalytic residue at P363 (P = 0.018); Loss of methylation at R364 (P = 0.0297); Gain of ubiquitination at K366 (P = 0.1204)",1.38629436111989,"R",-0.229,0,0,0,0.171
"127",364,"R364Q","MAPT",4,"","17:44061261:G:A","P10636",156.90243902439,"Loss of methylation at R364 (P = 0.0297); Loss of MoRF binding (P = 0.0491); Gain of ubiquitination at K366 (P = 0.0719); Gain of relative solvent accessibility (P = 0.1571); Gain of glycosylation at K366 (P = 0.2002)",1.38629436111989,"R",-0.229,0,0,0,0.171
"128",364,"R364W","MAPT",1,"","17:44061260:C:T","P10636",176.390243902439,"Loss of solvent accessibility (P = 0.0087); Gain of catalytic residue at P367 (P = 0.0259); Loss of methylation at R364 (P = 0.0297); Loss of relative solvent accessibility (P = 0.0981); Loss of ubiquitination at K366 (P = 0.1062)",0,"R",-0.229,0,0,0,0.171
"129",365,"G365E","MAPT",3,"","17:44061264:G:A","P10636",117.926829268293,"Loss of MoRF binding (P = 0.0432); Loss of methylation at R364 (P = 0.0491); Gain of solvent accessibility (P = 0.0789); Gain of glycosylation at P363 (P = 0.086); Loss of ubiquitination at K366 (P = 0.093)",1.09861228866811,"G",-0.311,0,0,0,0.264
"130",368,"V368I","MAPT",2,"","17:44061272:G:A","P10636",59.4634146341463,"Loss of methylation at R364 (P = 0.1197); Gain of ubiquitination at K366 (P = 0.1204); Loss of MoRF binding (P = 0.1294); Gain of glycosylation at K366 (P = 0.1934); Gain of stability (P = 0.2833)",0.693147180559945,"V",-0.299,0,0,0,0.677
"131",370,"R370Q","MAPT",1,"","17:44061279:G:A","P10636",195.878048780488,"Loss of MoRF binding (P = 0.0393); Gain of methylation at K366 (P = 0.0916); Loss of catalytic residue at R370 (P = 0.0977); Loss of ubiquitination at K366 (P = 0.1216); Gain of relative solvent accessibility (P = 0.1571)",0,"R",-0.115,0,0,0,-0.748
"132",372,"P372A","MAPT",2,"","17:44061284:C:G","P10636",147.158536585366,"Loss of methylation at K375 (P = 0.1039); Loss of solvent accessibility (P = 0.1322); Loss of relative solvent accessibility (P = 0.1807); Loss of ubiquitination at K375 (P = 0.1881); Gain of MoRF binding (P = 0.2258)",0.693147180559945,"P",-0.097,0,0,0,-0.839
"133",378,"M378L","MAPT",1,"","17:44064411:A:T","P10636",117.926829268293,"Loss of methylation at K383 (P = 0.0863); Loss of ubiquitination at K383 (P = 0.1741); Gain of glycosylation at S382 (P = 0.2948); Loss of catalytic residue at M378 (P = 0.3255); Loss of MoRF binding (P = 0.3909)",0,"M",-0.182,0,0,0,0.592
"134",378,"M378L","MAPT",1,"","17:44064411:A:C","P10636",117.926829268293,"Loss of methylation at K383 (P = 0.0863); Loss of ubiquitination at K383 (P = 0.1741); Gain of glycosylation at S382 (P = 0.2948); Loss of catalytic residue at M378 (P = 0.3255); Loss of MoRF binding (P = 0.3909)",0,"M",-0.182,0,0,0,0.592
"135",379,"V379D","MAPT",2,"","17:44064415:T:A","P10636",195.878048780488,"Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.0314); Loss of stability (P = 0.0332); Gain of ubiquitination at K383 (P = 0.0369); Loss of methylation at K383 (P = 0.0998)",0.693147180559945,"V",-0.237,0,0,0,0.395
"136",381,"K381E","MAPT",1,"","17:44064420:A:G","P10636",225.109756097561,"Loss of ubiquitination at K381 (P = 0.0063); Loss of MoRF binding (P = 0.0135); Loss of catalytic residue at K381 (P = 0.0276); Loss of methylation at K383 (P = 0.1146); Gain of relative solvent accessibility (P = 0.1571)",0,"K",-0.341,0,0,0,-0.595
"137",385,"G385R","MAPT",4,"","17:44064432:G:C","P10636",147.158536585366,"Loss of ubiquitination at K381 (P = 0.0272); Gain of methylation at K383 (P = 0.1139); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at S382 (P = 0.2266); Gain of MoRF binding (P = 0.2471)",1.38629436111989,"G",-0.862,0,0,0,-0.362
"138",385,"G385R","MAPT",4,"","17:44064432:G:A","P10636",147.158536585366,"Loss of ubiquitination at K381 (P = 0.0272); Gain of methylation at K383 (P = 0.1139); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at S382 (P = 0.2266); Gain of MoRF binding (P = 0.2471)",1.38629436111989,"G",-0.862,0,0,0,-0.362
"139",389,"D389N","MAPT",1,"","17:44064444:G:A","P10636",127.670731707317,"Loss of ubiquitination at K394 (P = 0.0365); Loss of solvent accessibility (P = 0.0387); Gain of methylation at K391 (P = 0.0582); Loss of relative solvent accessibility (P = 0.0676); Loss of stability (P = 0.2324)",0,"D",-0.896,0,0,0,0.614
"140",394,"K394R","MAPT",1,"","17:44064460:A:G","P10636",98.4390243902439,"Loss of ubiquitination at K394 (P = 0.0167); Loss of methylation at K394 (P = 0.0424); Loss of solvent accessibility (P = 0.1115); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at T397 (P = 0.2534)",0,"K",-0.786,0,0,0,-0.792
"141",395,"T395I","MAPT",2,"","17:44067245:C:T","P10636",78.9512195121951,"Loss of phosphorylation at T395 (P = 0.0096); Gain of methylation at K394 (P = 0.0537); Loss of ubiquitination at K394 (P = 0.0755); Loss of relative solvent accessibility (P = 0.0981); Gain of glycosylation at T397 (P = 0.1033)",0.693147180559945,"T",-0.646,0,0,0,-0.349
"142",396,"S396P","MAPT",1,"","17:44067247:T:C","P10636",117.926829268293,"Loss of phosphorylation at S396 (P = 0.0041); Gain of methylation at K394 (P = 0.0702); Loss of glycosylation at S396 (P = 0.0955); Loss of ubiquitination at K394 (P = 0.1322); Loss of MoRF binding (P = 0.2161)",0,"S",-0.482,0,0,0,-0.797
"143",398,"R398H","MAPT",2,"","17:44067254:G:A","P10636",215.365853658537,"Loss of MoRF binding (P = 0.0388); Gain of methylation at K394 (P = 0.0497); Gain of ubiquitination at K394 (P = 0.0598); Gain of glycosylation at T395 (P = 0.0682); Loss of phosphorylation at T397 (P = 0.2119)",0.693147180559945,"R",-0.412,0,0,0,-0.621
"144",405,"K405R","MAPT",1,"","17:44067275:A:G","P10636",244.59756097561,"Loss of methylation at K405 (P = 0.0295); Loss of ubiquitination at K405 (P = 0.0496); Gain of MoRF binding (P = 0.0899); Loss of glycosylation at P408 (P = 0.2929); Loss of solvent accessibility (P = 0.2953)",0,"K",-0.169,0,0,0,0.706
"145",406,"N406S","MAPT",1,"","17:44067278:A:G","P10636",254.341463414634,"Gain of phosphorylation at N406 (P = 0.0104); Gain of glycosylation at N406 (P = 0.0257); Loss of methylation at K405 (P = 0.1314); Loss of MoRF binding (P = 0.1439); Gain of relative solvent accessibility (P = 0.1571)",0,"N",-0.169,0,0,0,2.625
"146",408,"P408T","MAPT",3,"","17:44067283:C:A","P10636",186.134146341463,"Loss of catalytic residue at P408 (P = 0.0197); Gain of phosphorylation at P408 (P = 0.0275); Loss of stability (P = 0.0537); Gain of MoRF binding (P = 0.0566); Loss of glycosylation at P408 (P = 0.1022)",1.09861228866811,"P",-0.196,0,0,0,0.033
"147",412,"P412S","MAPT",1,"","17:44067295:C:T","P10636",117.926829268293,"Gain of phosphorylation at P412 (P = 0.021); Gain of MoRF binding (P = 0.0585); Loss of glycosylation at K413 (P = 0.1057); Loss of methylation at K413 (P = 0.1391); Loss of stability (P = 0.1842)",0,"P",-0.274,0,0,0,-0.379
"148",416,"T416A","MAPT",1,"","17:44067307:A:G","P10636",195.878048780488,"Loss of phosphorylation at T416 (P = 0.0059); Loss of glycosylation at T416 (P = 0.0153); Loss of solvent accessibility (P = 0.1177); Loss of methylation at K413 (P = 0.1713); Loss of relative solvent accessibility (P = 0.1807)",0,"T",-0.58,0,0,0,-0.246
"149",424,"I424S","MAPT",1,"","17:44067332:T:G","P10636",234.853658536585,"Gain of phosphorylation at I424 (P = 0.0068); Gain of glycosylation at I424 (P = 0.0183); Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.0854); Loss of stability (P = 0.0866)",0,"I",-0.186,0,0,0,-0.44
"150",424,"I424V","MAPT",1,"","17:44067331:A:G","P10636",195.878048780488,"Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.0674); Gain of glycosylation at S419 (P = 0.1305); Gain of phosphorylation at S427 (P = 0.5581); Loss of sheet (P = 0.6423)",0,"I",-0.186,0,0,0,-0.44
"151",428,"S428R","MAPT",1,"","17:44067345:C:G","P10636",225.109756097561,"Loss of glycosylation at S428 (P = 0.0088); Loss of phosphorylation at S428 (P = 0.0119); Gain of catalytic residue at S428 (P = 0.0314); Gain of solvent accessibility (P = 0.3304); Loss of stability (P = 0.5068)",0,"S",0.231,0.502,0,0.231,-0.722
"152",428,"S428R","MAPT",1,"","17:44067343:A:C","P10636",225.109756097561,"Loss of glycosylation at S428 (P = 0.0088); Loss of phosphorylation at S428 (P = 0.0119); Gain of catalytic residue at S428 (P = 0.0314); Gain of solvent accessibility (P = 0.3304); Loss of stability (P = 0.5068)",0,"S",0.231,0.502,0,0.231,-0.722
"153",428,"S428R","MAPT",1,"","17:44067345:C:A","P10636",225.109756097561,"Loss of glycosylation at S428 (P = 0.0088); Loss of phosphorylation at S428 (P = 0.0119); Gain of catalytic residue at S428 (P = 0.0314); Gain of solvent accessibility (P = 0.3304); Loss of stability (P = 0.5068)",0,"S",0.231,0.502,0,0.231,-0.722
"154",434,"E434Q","MAPT",1,"","17:44067361:G:C","P10636",283.573170731707,"Loss of catalytic residue at E434 (P = 0.046); Loss of solvent accessibility (P = 0.0721); Loss of glycosylation at P433 (P = 0.0831); Loss of relative solvent accessibility (P = 0.1807); Gain of MoRF binding (P = 0.431)",0,"E",-0.137,0,0,0,0.139
"155",437,"S437F","MAPT",1,"","17:44067371:C:T","P10636",127.670731707317,"Loss of phosphorylation at S437 (P = 0.0065); Loss of glycosylation at S437 (P = 0.0215); Gain of catalytic residue at S437 (P = 0.1031); Gain of solvent accessibility (P = 0.1376); Loss of MoRF binding (P = 0.2549)",0,"S",-0.083,0,0,0,-0.716
"156",439,"P439S","MAPT",1,"","17:44067376:C:T","P10636",127.670731707317,"Gain of phosphorylation at P439 (P = 0.0096); Gain of MoRF binding (P = 0.0695); Loss of glycosylation at S437 (P = 0.1174); Loss of stability (P = 0.1319); Loss of methylation at K440 (P = 0.1424)",0,"P",-0.161,0,0,0,-0.644
"157",442,"V442I","MAPT",1,"","17:44067385:G:A","P10636",88.6951219512195,"Gain of MoRF binding (P = 0.1396); Loss of glycosylation at S437 (P = 0.1701); Loss of phosphorylation at T446 (P = 0.2244); Gain of methylation at K440 (P = 0.2628); Gain of catalytic residue at S444 (P = 0.2881)",0,"V",0.132,0.756,0.108,0.088,0.219
"158",461,"G461E","MAPT",7,"","17:44068827:G:A","P10636",205.621951219512,"Gain of solvent accessibility (P = 0.024); Gain of ubiquitination at K460 (P = 0.0415); Loss of MoRF binding (P = 0.082); Gain of methylation at K465 (P = 0.2458); Loss of glycosylation at K460 (P = 0.246)",1.94591014905531,"G",-0.456,0,0,0,0.759
"159",469,"A469S","MAPT",163,"","17:44068850:G:T","P10636",156.90243902439,"Gain of phosphorylation at A469 (P = 0.0153); Gain of glycosylation at A469 (P = 0.0162); Gain of relative solvent accessibility (P = 0.09); Gain of ubiquitination at K467 (P = 0.1278); Gain of solvent accessibility (P = 0.1319)",5.09375020080676,"A",-0.279,0,0,0,0.58
"160",476,"P476L","MAPT",1,"","17:44068872:C:T","P10636",273.829268292683,"Loss of glycosylation at P476 (P = 0.0375); Gain of MoRF binding (P = 0.0653); Loss of methylation at K480 (P = 0.0666); Gain of ubiquitination at K480 (P = 0.0972); Loss of relative solvent accessibility (P = 0.0981)",0,"P",-0.553,0,0,0,1.182
"161",482,"Q482P","MAPT",4,"","17:44068890:A:C","P10636",176.390243902439,"Gain of glycosylation at Q482 (P = 0.0342); Loss of MoRF binding (P = 0.0585); Gain of methylation at R487 (P = 0.1389); Loss of ubiquitination at K480 (P = 0.1423); Gain of catalytic residue at G481 (P = 0.1627)",1.38629436111989,"Q",-0.688,0,0,0,1.487
"162",482,"Q482R","MAPT",4,"","17:44068890:A:G","P10636",186.134146341463,"Gain of methylation at Q482 (P = 0.0094); Gain of MoRF binding (P = 0.0526); Gain of catalytic residue at Q482 (P = 0.0953); Loss of ubiquitination at K480 (P = 0.1091); Loss of glycosylation at K480 (P = 0.1466)",1.38629436111989,"Q",-0.688,0,0,0,1.487
"163",483,"A483V","MAPT",1,"","17:44068893:C:T","P10636",186.134146341463,"Loss of relative solvent accessibility (P = 0.0981); Loss of ubiquitination at K480 (P = 0.1264); Gain of MoRF binding (P = 0.1382); Gain of methylation at K480 (P = 0.1536); Loss of phosphorylation at T486 (P = 0.1705)",0,"A",-0.492,0,0,0,0.39
"164",485,"A485T","MAPT",1,"","17:44068898:G:A","P10636",244.59756097561,"Gain of glycosylation at A485 (P = 0.0067); Gain of phosphorylation at A485 (P = 0.0596); Gain of catalytic residue at A485 (P = 0.0825); Gain of methylation at K480 (P = 0.0962); Loss of MoRF binding (P = 0.1086)",0,"A",-0.365,0,0,0,-0.143
"165",487,"R487K","MAPT",1,"","17:44068905:G:A","P10636",273.829268292683,"Gain of methylation at R487 (P = 0.021); Gain of ubiquitination at R487 (P = 0.03); Loss of MoRF binding (P = 0.0738); Gain of glycosylation at R487 (P = 0.0973); Loss of catalytic residue at R487 (P = 0.1478)",0,"R",-0.331,0,0,0,-0.224
"166",492,"T492P","MAPT",2,"","17:44068919:A:C","P10636",205.621951219512,"Loss of phosphorylation at T492 (P = 0.0034); Gain of catalytic residue at T492 (P = 0.0055); Loss of MoRF binding (P = 0.0688); Gain of glycosylation at P493 (P = 0.0846); Gain of ubiquitination at K491 (P = 0.115)",0.693147180559945,"T",-0.259,0,0,0,-0.411
"167",494,"P494L","MAPT",1,"","17:44068926:C:T","P10636",176.390243902439,"Loss of glycosylation at P494 (P = 0.0078); Loss of catalytic residue at P493 (P = 0.0219); Gain of stability (P = 0.0311); Loss of ubiquitination at K491 (P = 0.0587); Gain of MoRF binding (P = 0.0744)",0,"P",-0.357,0,0,0,0.353
"168",503,"G503S","MAPT",1,"","17:44068952:G:A","P10636",225.109756097561,"Gain of phosphorylation at G503 (P = 7e-04); Gain of glycosylation at G503 (P = 0.0113); Gain of solvent accessibility (P = 0.1683); Loss of ubiquitination at K507 (P = 0.321); Gain of methylation at K507 (P = 0.4965)",0,"G",-0.478,0,0,0,-0.703
"169",511,"R511C","MAPT",1,"","17:44073788:C:T","P10636",234.853658536585,"Gain of glycosylation at S508 (P = 0.0758); Loss of MoRF binding (P = 0.1399); Gain of catalytic residue at G513 (P = 0.1731); Loss of solvent accessibility (P = 0.2668); Loss of ubiquitination at K507 (P = 0.2936)",0,"R",-0.493,0,0,0,-0.947
"170",521,"G521S","MAPT",1,"","17:44073818:G:A","P10636",176.390243902439,"Gain of phosphorylation at G521 (P = 4e-04); Gain of glycosylation at G521 (P = 0.0055); Loss of catalytic residue at P517 (P = 0.0852); Loss of methylation at R526 (P = 0.1152); Gain of solvent accessibility (P = 0.1683)",0,"G",-0.444,0,0,0,-0.422
"171",528,"R528C","MAPT",3,"","17:44073839:C:T","P10636",215.365853658537,"Loss of methylation at R528 (P = 0.0265); Gain of relative solvent accessibility (P = 0.0479); Loss of MoRF binding (P = 0.0829); Gain of glycosylation at P523 (P = 0.1117); Loss of catalytic residue at S527 (P = 0.2345)",1.09861228866811,"R",-0.334,0,0,0,-0.395
"172",528,"R528H","MAPT",1,"","17:44073840:G:A","P10636",186.134146341463,"Loss of methylation at R528 (P = 0.0265); Gain of relative solvent accessibility (P = 0.0479); Loss of MoRF binding (P = 0.0967); Gain of solvent accessibility (P = 0.0971); Gain of glycosylation at S531 (P = 0.1424)",0,"R",-0.334,0,0,0,-0.395
"173",529,"T529N","MAPT",1,"","17:44073843:C:A","P10636",205.621951219512,"Loss of phosphorylation at T529 (P = 7e-04); Loss of glycosylation at S527 (P = 0.1013); Loss of methylation at R526 (P = 0.1429); Gain of MoRF binding (P = 0.2209); Loss of stability (P = 0.3382)",0,"T",-0.318,0,0,0,-0.719
"174",534,"T534I","MAPT",3,"","17:44073858:C:T","P10636",117.926829268293,"Loss of glycosylation at T534 (P = 0.0065); Loss of phosphorylation at T534 (P = 0.0083); Gain of catalytic residue at P536 (P = 0.064); Loss of MoRF binding (P = 0.1365); Loss of methylation at R538 (P = 0.4691)",1.09861228866811,"T",-0.307,0,0,0,-0.675
"175",538,"R538Q","MAPT",1,"","17:44073870:G:A","P10636",205.621951219512,"Gain of relative solvent accessibility (P = 0.0166); Gain of solvent accessibility (P = 0.0171); Loss of MoRF binding (P = 0.0174); Gain of glycosylation at K541 (P = 0.1149); Gain of ubiquitination at K542 (P = 0.1317)",0,"R",-0.416,0,0,0,-0.291
"176",556,"A556S","MAPT",93,"","17:44073923:G:T","P10636",127.670731707317,"Gain of phosphorylation at A556 (P = 0.0067); Loss of helix (P = 0.0376); Gain of glycosylation at A556 (P = 0.0492); Gain of loop (P = 0.0851); Gain of methylation at K551 (P = 0.0891)",4.53259949315326,"A",-0.409,0,0,0,0.128
"177",558,"S558G","MAPT",1,"","17:44073929:A:G","P10636",166.646341463415,"Loss of phosphorylation at S558 (P = 0.0113); Gain of relative solvent accessibility (P = 0.0275); Gain of methylation at R559 (P = 0.0415); Loss of glycosylation at S558 (P = 0.0419); Gain of helix (P = 0.0854)",0,"S",-0.315,0,0,0,-0.28
"178",563,"A563T","MAPT",24,"","17:44073944:G:A","P10636",234.853658536585,"Gain of glycosylation at A563 (P = 0.0023); Gain of phosphorylation at A563 (P = 0.0254); Loss of MoRF binding (P = 0.1123); Loss of stability (P = 0.119); Loss of methylation at R559 (P = 0.2173)",3.17805383034795,"A",-0.007,0.013,0,-0.007,-0.359
"179",565,"V565L","MAPT",9,"","17:44073950:G:C","P10636",293.317073170732,"Loss of MoRF binding (P = 0.0915); Gain of glycosylation at P566 (P = 0.1073); Gain of catalytic residue at V565 (P = 0.1945); Loss of phosphorylation at T562 (P = 0.3858); Loss of helix (P = 0.3949)",2.19722457733622,"V",0.091,0.111,0,0.091,-0.503
"180",565,"V565L","MAPT",9,"","17:44073950:G:T","P10636",293.317073170732,"Loss of MoRF binding (P = 0.0915); Gain of glycosylation at P566 (P = 0.1073); Gain of catalytic residue at V565 (P = 0.1945); Loss of phosphorylation at T562 (P = 0.3858); Loss of helix (P = 0.3949)",2.19722457733622,"V",0.091,0.111,0,0.091,-0.503
"181",568,"P568A","MAPT",1,"","17:44073959:C:G","P10636",390.756097560976,"Gain of MoRF binding (P = 0.0381); Gain of helix (P = 0.0425); Loss of loop (P = 0.0512); Loss of methylation at K571 (P = 0.0693); Loss of glycosylation at P568 (P = 0.1265)",0,"P",0.034,0,0,0,-0.878
"182",573,"V573I","MAPT",1,"","17:44073974:G:A","P10636",614.865853658537,"Loss of methylation at K574 (P = 0.0641); Loss of ubiquitination at K574 (P = 0.0724); Loss of MoRF binding (P = 0.1415); Loss of glycosylation at S575 (P = 0.1441); Gain of helix (P = 0.1736)",0,"V",-0.209,0,0,0,-0.614
"183",574,"K574T","MAPT",0.1,"P","17:44073978:A:C","P10636",517.426829268293,"Loss of methylation at K574 (P = 0.0097); Loss of ubiquitination at K574 (P = 0.0107); Gain of glycosylation at K574 (P = 0.0461); Loss of MoRF binding (P = 0.0659); Loss of helix (P = 0.079)",-2.30258509299405,"K",-0.205,0,0,0,0.509
"184",583,"L583V","MAPT",0.1,"P","17:44074004:C:G","P10636",556.40243902439,"Gain of methylation at K584 (P = 0.0382); Gain of MoRF binding (P = 0.0901); Loss of stability (P = 0.104); Gain of ubiquitination at K584 (P = 0.123); Loss of catalytic residue at L583 (P = 0.1757)",-2.30258509299405,"L",-0.581,0,0,0,-0.702
"185",589,"G589V","MAPT",0.1,"P","17:44074023:G:T","P10636",673.329268292683,"Loss of ubiquitination at K591 (P = 0.0598); Gain of MoRF binding (P = 0.1002); Gain of methylation at K584 (P = 0.1046); Loss of glycosylation at K591 (P = 0.2578); Loss of catalytic residue at G588 (P = 0.2808)",-2.30258509299405,"G",-0.353,0,0,0,-0.826
"186",596,"N596K","MAPT",0.1,"P","17:44087690:T:G","P10636",683.073170731707,"Gain of catalytic residue at N596 (P = 0.0171); Loss of ubiquitination at K591 (P = 0.0211); Gain of MoRF binding (P = 0.034); Gain of solvent accessibility (P = 0.0354); Gain of relative solvent accessibility (P = 0.0479)",-2.30258509299405,"N",0.076,0.25,0,0.105,-0.931
"187",596,"N596K","MAPT",0.1,"P","17:44087690:T:A","P10636",683.073170731707,"Gain of catalytic residue at N596 (P = 0.0171); Loss of ubiquitination at K591 (P = 0.0211); Gain of MoRF binding (P = 0.034); Gain of solvent accessibility (P = 0.0354); Gain of relative solvent accessibility (P = 0.0479)",-2.30258509299405,"N",0.076,0.25,0,0.105,-0.931
"188",597,"K597R","MAPT",1,"","17:44087692:A:G","P10636",468.707317073171,"Gain of MoRF binding (P = 0.0704); Loss of ubiquitination at K597 (P = 0.0982); Loss of disorder (P = 0.1073); Gain of methylation at K598 (P = 0.2086); Loss of sheet (P = 0.302)",0,"K",0.134,0.25,0,0.105,-1.03
"189",618,"P618L","MAPT",0.1,"P","17:44087755:C:T","P10636",800,"Gain of catalytic residue at P618 (P = 0.024); Loss of disorder (P = 0.0325); Loss of ubiquitination at K615 (P = 0.0709); Gain of sheet (P = 0.1208); Gain of MoRF binding (P = 0.1587)",-2.30258509299405,"P",-0.044,0,0,0,-0.882
"190",618,"P618S","MAPT",0.1,"P","17:44087754:C:T","P10636",770.768292682927,"Gain of catalytic residue at P618 (P = 0.0465); Gain of sheet (P = 0.0477); Gain of relative solvent accessibility (P = 0.09); Gain of ubiquitination at K615 (P = 0.0918); Gain of MoRF binding (P = 0.1007)",-2.30258509299405,"P",-0.044,0,0,0,-0.882
"191",620,"G620V","MAPT",0.1,"P","17:44087761:G:T","P10636",761.024390243902,"Loss of ubiquitination at K615 (P = 0.0505); Loss of disorder (P = 0.0584); Gain of sheet (P = 0.1208); Loss of relative solvent accessibility (P = 0.3219); Gain of MoRF binding (P = 0.3398)",-2.30258509299405,"G",-0.038,0,0,0,-1.095
"192",621,"G621S","MAPT",2,"","17:44087763:G:A","P10636",790.256097560976,"Gain of relative solvent accessibility (P = 0.0479); Gain of phosphorylation at G621 (P = 0.0762); Gain of disorder (P = 0.0936); Gain of solvent accessibility (P = 0.11); Loss of sheet (P = 0.1398)",0.693147180559945,"G",0.192,2.478,0.31,0.29,-0.971
"193",622,"S622N","MAPT",0.1,"P","17:44087767:G:A","P10636",585.634146341463,"Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.0766); Loss of disorder (P = 0.1047); Gain of catalytic residue at S622 (P = 0.189); Loss of sheet (P = 0.1907)",-2.30258509299405,"S",0.391,2.478,0.31,0.29,-1.022
"194",634,"K634M","MAPT",0.1,"P","17:44091643:A:T","P10636",663.585365853658,"Gain of catalytic residue at V630 (P = 0.0127); Loss of ubiquitination at K634 (P = 0.0155); Loss of disorder (P = 0.0289); Gain of glycosylation at S637 (P = 0.086); Loss of MoRF binding (P = 0.0944)",-2.30258509299405,"K",0.036,0.093,0,0.027,-0.623
"195",637,"S637F","MAPT",0.1,"P","17:44091652:C:T","P10636",702.560975609756,"Loss of disorder (P = 0.0034); Loss of ubiquitination at K634 (P = 0.0369); Gain of sheet (P = 0.0477); Loss of glycosylation at S637 (P = 0.08); Loss of loop (P = 0.0804)",-2.30258509299405,"S",0.138,0.158,0,0.138,-1.095
"196",654,"V654M","MAPT",0.1,"P","17:44095995:G:A","P10636",722.048780487805,"Gain of ubiquitination at K657 (P = 0.14); Loss of sheet (P = 0.1501); Gain of phosphorylation at S658 (P = 0.2252); Gain of relative solvent accessibility (P = 0.281); Gain of catalytic residue at V654 (P = 0.3517)",-2.30258509299405,"V",-0.366,0,0,0,-1.077
"197",659,"E659V","MAPT",0.1,"P","17:44096011:A:T","P10636",673.329268292683,"Gain of MoRF binding (P = 0.0249); Loss of ubiquitination at K664 (P = 0.0334); Gain of sheet (P = 0.039); Loss of disorder (P = 0.0612); Loss of catalytic residue at E659 (P = 0.0612)",-2.30258509299405,"E",-0.13,0,0,0,-0.952
"198",669,"S669L","MAPT",0.1,"P","17:44096041:C:T","P10636",644.09756097561,"Loss of disorder (P = 0.0143); Loss of glycosylation at S669 (P = 0.0194); Loss of phosphorylation at S669 (P = 0.0387); Gain of relative solvent accessibility (P = 0.0479); Gain of catalytic residue at S669 (P = 0.06)",-2.30258509299405,"S",-0.227,0,0,0,-1.027
"199",669,"S669P","MAPT",2,"","17:44096040:T:C","P10636",595.378048780488,"Gain of relative solvent accessibility (P = 0.0082); Loss of glycosylation at S669 (P = 0.0242); Gain of solvent accessibility (P = 0.0256); Loss of phosphorylation at S669 (P = 0.0387); Loss of stability (P = 0.0797)",0.693147180559945,"S",-0.227,0,0,0,-1.027
"200",671,"I671T","MAPT",2,"","17:44096047:T:C","P10636",692.817073170732,"Gain of relative solvent accessibility (P = 0.0082); Gain of solvent accessibility (P = 0.0202); Loss of stability (P = 0.0218); Loss of helix (P = 0.0376); Gain of disorder (P = 0.0436)",0.693147180559945,"I",-0.261,0,0,0,-0.935
"201",675,"D675G","MAPT",1,"","17:44096059:A:G","P10636",653.841463414634,"Loss of catalytic residue at D675 (P = 0.0051); Gain of MoRF binding (P = 0.0462); Gain of sheet (P = 0.0827); Loss of stability (P = 0.1052); Loss of ubiquitination at K670 (P = 0.1139)",0,"D",0.048,0.19,0,0.075,-0.591
"202",680,"V680I","MAPT",2,"","17:44096073:G:A","P10636",585.634146341463,"Gain of catalytic residue at V680 (P = 0.1713); Gain of disorder (P = 0.2354); Loss of phosphorylation at T678 (P = 0.2621); Loss of sheet (P = 0.302); Loss of glycosylation at T678 (P = 0.3298)",0.693147180559945,"V",-0.378,0,0,0,-0.7
"203",686,"K686I","MAPT",0.1,"P","17:44096092:A:T","P10636",595.378048780488,"Loss of disorder (P = 0.0187); Loss of methylation at K686 (P = 0.0305); Gain of ubiquitination at K687 (P = 0.0326); Gain of sheet (P = 0.039); Loss of glycosylation at K686 (P = 0.0671)",-2.30258509299405,"K",-0.535,0,0,0,-0.525
"204",696,"R696C","MAPT",1,"","17:44101346:C:T","P10636",400.5,"Loss of MoRF binding (P = 0.0209); Loss of disorder (P = 0.0354); Gain of methylation at K692 (P = 0.0439); Loss of catalytic residue at R696 (P = 0.0652); Gain of ubiquitination at K700 (P = 0.1092)",0,"R",-0.359,0,0,0,-1.132
"205",700,"K700E","MAPT",1,"","17:44101358:A:G","P10636",303.060975609756,"Loss of ubiquitination at K700 (P = 0.0148); Loss of MoRF binding (P = 0.0302); Gain of helix (P = 0.062); Loss of loop (P = 0.1242); Loss of sheet (P = 0.1907)",0,"K",-0.651,0,0,0,-0.927
"206",702,"K702E","MAPT",1,"","17:44101364:A:G","P10636",361.524390243902,"Loss of ubiquitination at K702 (P = 0.0148); Loss of MoRF binding (P = 0.0521); Loss of helix (P = 0.079); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.1116)",0,"K",-0.75,0,0,0,-1.034
"207",706,"G706R","MAPT",2,"","17:44101376:G:C","P10636",527.170731707317,"Loss of ubiquitination at K702 (P = 0.0303); Gain of solvent accessibility (P = 0.0306); Gain of MoRF binding (P = 0.0374); Loss of loop (P = 0.1242); Gain of disorder (P = 0.1532)",0.693147180559945,"G",-0.128,0,0,0,-0.965
"208",706,"G706R","MAPT",2,"","17:44101376:G:A","P10636",527.170731707317,"Loss of ubiquitination at K702 (P = 0.0303); Gain of solvent accessibility (P = 0.0306); Gain of MoRF binding (P = 0.0374); Loss of loop (P = 0.1242); Gain of disorder (P = 0.1532)",0.693147180559945,"G",-0.128,0,0,0,-0.965
"209",706,"G706R","MAPT",0.1,"P","17:44101376:G:C","P10636",527.170731707317,"Loss of ubiquitination at K702 (P = 0.0303); Gain of solvent accessibility (P = 0.0306); Gain of MoRF binding (P = 0.0374); Loss of loop (P = 0.1242); Gain of disorder (P = 0.1532)",-2.30258509299405,"G",-0.128,0,0,0,-0.965
"210",706,"G706R","MAPT",0.1,"P","17:44101376:G:A","P10636",527.170731707317,"Loss of ubiquitination at K702 (P = 0.0303); Gain of solvent accessibility (P = 0.0306); Gain of MoRF binding (P = 0.0374); Loss of loop (P = 0.1242); Gain of disorder (P = 0.1532)",-2.30258509299405,"G",-0.128,0,0,0,-0.965
"211",707,"A707V","MAPT",1,"","17:44101380:C:T","P10636",293.317073170732,"Loss of ubiquitination at K712 (P = 0.0591); Loss of disorder (P = 0.0978); Loss of loop (P = 0.1242); Gain of sheet (P = 0.1945); Loss of phosphorylation at T703 (P = 0.1953)",0,"A",-0.209,0,0,0,-1.072
"212",715,"V715A","MAPT",1,"","17:44101404:T:C","P10636",205.621951219512,"Gain of disorder (P = 0.0749); Loss of sheet (P = 0.0817); Gain of relative solvent accessibility (P = 0.09); Gain of glycosylation at S713 (P = 0.1589); Gain of phosphorylation at S717 (P = 0.1749)",0,"V",0.142,0.162,0,0.142,-0.41
"213",715,"V715M","MAPT",1,"","17:44101403:G:A","P10636",254.341463414634,"Loss of sheet (P = 0.0817); Gain of relative solvent accessibility (P = 0.09); Gain of disorder (P = 0.1023); Gain of solvent accessibility (P = 0.1045); Gain of phosphorylation at T720 (P = 0.1113)",0,"V",0.142,0.162,0,0.142,-0.41
"214",723,"R723Q","MAPT",1,"","17:44101428:G:A","P10636",127.670731707317,"Loss of phosphorylation at S726 (P = 0.0591); Gain of glycosylation at T720 (P = 0.0671); Gain of relative solvent accessibility (P = 0.1066); Loss of sheet (P = 0.1907); Loss of catalytic residue at R723 (P = 0.1985)",0,"R",-0.368,0,0,0,-0.767
"215",723,"R723W","MAPT",0.1,"P","17:44101427:C:T","P10636",342.036585365854,"Loss of disorder (P = 0.0292); Loss of phosphorylation at S726 (P = 0.0504); Gain of glycosylation at T720 (P = 0.1114); Gain of sheet (P = 0.1208); Gain of catalytic residue at N727 (P = 0.1329)",-2.30258509299405,"R",-0.368,0,0,0,-0.767
"216",723,"R723W","MAPT",1,"","17:44101427:C:T","P10636",342.036585365854,"Loss of disorder (P = 0.0292); Loss of phosphorylation at S726 (P = 0.0504); Gain of glycosylation at T720 (P = 0.1114); Gain of sheet (P = 0.1208); Gain of catalytic residue at N727 (P = 0.1329)",0,"R",-0.368,0,0,0,-0.767
"217",727,"N727H","MAPT",1,"","17:44101439:A:C","P10636",78.9512195121951,"Gain of sheet (P = 0.1208); Gain of relative solvent accessibility (P = 0.1259); Gain of phosphorylation at S729 (P = 0.1455); Gain of solvent accessibility (P = 0.199); Loss of loop (P = 0.2237)",0,"N",-0.228,0,0,0,-0.861
"218",730,"S730F","MAPT",1,"","17:44101449:C:T","P10636",205.621951219512,"Loss of disorder (P = 0.0015); Loss of glycosylation at T731 (P = 0.0404); Loss of phosphorylation at S730 (P = 0.0514); Loss of loop (P = 0.0986); Gain of relative solvent accessibility (P = 0.1259)",0,"S",-0.019,0.074,0,0.017,-1.091
"219",731,"T731A","MAPT",2,"","17:44101451:A:G","P10636",49.719512195122,"Loss of glycosylation at T731 (P = 0.016); Loss of sheet (P = 0.1158); Gain of catalytic residue at T731 (P = 0.1283); Gain of relative solvent accessibility (P = 0.1571); Loss of stability (P = 0.1983)",0.693147180559945,"T",-0.062,0,0,0,-0.664
"220",732,"G732S","MAPT",3,"","17:44101454:G:A","P10636",371.268292682927,"Gain of phosphorylation at G732 (P = 0.0369); Gain of disorder (P = 0.0682); Loss of sheet (P = 0.0817); Gain of glycosylation at G732 (P = 0.1124); Loss of stability (P = 0.1246)",1.09861228866811,"G",0.11,0.211,0,0.085,-1.093
"221",735,"D735N","MAPT",2,"","17:44101463:G:A","P10636",312.80487804878,"Gain of catalytic residue at D735 (P = 0.0237); Loss of stability (P = 0.069); Gain of sheet (P = 0.0827); Loss of disorder (P = 0.1303); Loss of phosphorylation at S733 (P = 0.1345)",0.693147180559945,"D",-0.114,0,0,0,-0.565
"222",736,"M736T","MAPT",1,"","17:44101467:T:C","P10636",186.134146341463,"Gain of glycosylation at M736 (P = 0.017); Loss of sheet (P = 0.0457); Gain of relative solvent accessibility (P = 0.0479); Gain of phosphorylation at M736 (P = 0.0681); Loss of stability (P = 0.0714)",0,"M",-0.199,0,0,0,-0.585
"223",736,"M736V","MAPT",1,"","17:44101466:A:G","P10636",137.414634146341,"Gain of catalytic residue at M736 (P = 0.0184); Gain of sheet (P = 0.0827); Loss of disorder (P = 0.1706); Loss of phosphorylation at S739 (P = 0.1899); Gain of glycosylation at S733 (P = 0.2538)",0,"M",-0.199,0,0,0,-0.585
"224",741,"Q741K","MAPT",4,"","17:44101481:C:A","P10636",575.890243902439,"Gain of solvent accessibility (P = 0.0071); Gain of ubiquitination at Q741 (P = 0.009); Gain of relative solvent accessibility (P = 0.0166); Gain of glycosylation at Q741 (P = 0.0701); Gain of phosphorylation at S739 (P = 0.1171)",1.38629436111989,"Q",0.122,0.142,0,0.122,-1.05
"225",743,"A743T","MAPT",3,"","17:44101487:G:A","P10636",78.9512195121951,"Gain of glycosylation at A743 (P = 0.0054); Gain of relative solvent accessibility (P = 0.09); Gain of loop (P = 0.1069); Gain of solvent accessibility (P = 0.1683); Gain of helix (P = 0.1736)",1.09861228866811,"A",-0.401,0,0,0,-0.861
"226",744,"T744M","MAPT",2,"","17:44101491:C:T","P10636",566.146341463415,"Gain of helix (P = 0.0199); Loss of loop (P = 0.0288); Loss of glycosylation at T744 (P = 0.0314); Loss of phosphorylation at T744 (P = 0.1475); Gain of solvent accessibility (P = 0.199)",0.693147180559945,"T",-0.089,0,0,0,-1.082
"227",746,"A746T","MAPT",1,"","17:44101496:G:A","P10636",78.9512195121951,"Loss of helix (P = 0.0167); Gain of relative solvent accessibility (P = 0.0215); Gain of loop (P = 0.024); Gain of solvent accessibility (P = 0.0456); Gain of phosphorylation at A746 (P = 0.0884)",0,"A",-0.062,0,0,0,-1.144
"228",748,"E748K","MAPT",1,"","17:44101502:G:A","P10636",137.414634146341,"Gain of ubiquitination at E748 (P = 0.0101); Gain of MoRF binding (P = 0.024); Gain of helix (P = 0.062); Loss of loop (P = 0.0804); Gain of relative solvent accessibility (P = 0.0999)",0,"E",0.023,0.128,0,0.023,-0.94
"229",752,"S752F","MAPT",1,"","17:44101515:C:T","P10636",225.109756097561,"Loss of disorder (P = 0); Loss of ubiquitination at K755 (P = 0.0353); Gain of methylation at K755 (P = 0.0373); Loss of phosphorylation at S752 (P = 0.051); Gain of catalytic residue at S752 (P = 0.173)",0,"S",-0.33,0,0,0,-1.088
